Continue to learn
On April 18, 2023, the launching ceremony for Maxvax’s production platform for innovative vaccines was successfully held. The ceremony took place in the Life Science & Tech Park of Lingang Special Area, Shanghai. This marks that Maxvax is embarking on a new journey of commercializing its R&D achievements and demonstrates its determination and confidence to promote industrialization.
more >On the afternoon of August 12, 2022, an eight-person expert team led by Party Secretary Mr. Jun Yuan and Deputy Director Ms. Lei Yang of the Sichuan Institute for Drug Control visited MAXVAX. Among those were experts from the Institute for Inspection of Biological Products and the Biological Sample Testing Center. Maxvax’s General Manager Dr. Dexiang Chen, quality control team, R&D team, operation management, and key technicians gave the visiting team a warm welcome. The two sides had a meeting, after which the expert team visited our laboratory and pilot workshop.
more >On January 08, 2023, the enrollment was initiated for Phase II clinical study for recombinant rotavirus subunit vaccine independently developed by MAXVAX Biotechnology Limited Liability Company (hereinafter referred to as "Maxvax Biotech"). Despite that the clinical study was repeatedly postponed due to various factors at the end of last year, Maxvax Biotech and the investigators seized the "window period" together with the study sites - Henan Provincial Center for Disease Control and Prevention, Ningling County Center for Disease Control and Prevention, and Shangqiu Liangyuan District Center for Disease Control and Prevention - to overcome difficulties such as
more >Recently, Chengdu Maxvax Biotechnology ("Maxvax Biotech") announced that it has raised nearly RMB 500 million (approx. $74 million) from a Series B funding led by China Life Equity Investment and participated by the original shareholders Sherpa Healthcare Partners and GL Ventures, with follow-up investments from two new investors, Shizhen Capital and Xinshang Capital. The fund will mainly be used for the clinical trials of the company’s multiple vaccine pipelines, the construction of its Shanghai production base, and the expansion and improvement of its talent team.
more >Maxvax Biotech's new pipeline started the enrollment for clinical study and set another milestone in this year, standing forefront in the industry and achieving accelerated development.
more >Maxvax Biotech held a grand commencement ceremony for the "Innovative Vaccine Production Platform Project" of Shanghai Maxvax Biotech, a wholly-owned subsidiary of Chengdu Maxvax Biotech, in the Lingang New Area of Shanghai on June 27, 2022. Leaders of Shanghai Lingang Fengxian Economic Development Company (Chairman Mr. Linkun Zou, Assistant General Manager Ms. Aiying Ding, and Deputy Director of Project Promotion Department Mr. Jie Duan) and leaders of Maxvax (Deputy General Manager Mr. Yi Jin and Mr. Yichun Dong), and other leaders and partners attended the event.
more >
On April 18, 2023, the launching ceremony for Maxvax’s production platform for innovative vaccines was successfully held. The ceremony took place in the Life Science & Tech Park of Lingang Special Area, Shanghai. This marks that Maxvax is embarking on a new journey of commercializing its R&D achievements and demonstrates its determination and confidence to promote industrialization.
more >
On January 08, 2023, the enrollment was initiated for Phase II clinical study for recombinant rotavirus subunit vaccine independently developed by MAXVAX Biotechnology Limited Liability Company (hereinafter referred to as "Maxvax Biotech"). Despite that the clinical study was repeatedly postponed due to various factors at the end of last year, Maxvax Biotech and the investigators seized the "window period" together with the study sites - Henan Provincial Center for Disease Control and Prevention, Ningling County Center for Disease Control and Prevention, and Shangqiu Liangyuan District Center for Disease Control and Prevention - to overcome difficulties such as
more >
Maxvax Biotech's new pipeline started the enrollment for clinical study and set another milestone in this year, standing forefront in the industry and achieving accelerated development.
more >
On the afternoon of August 12, 2022, an eight-person expert team led by Party Secretary Mr. Jun Yuan and Deputy Director Ms. Lei Yang of the Sichuan Institute for Drug Control visited MAXVAX. Among those were experts from the Institute for Inspection of Biological Products and the Biological Sample Testing Center. Maxvax’s General Manager Dr. Dexiang Chen, quality control team, R&D team, operation management, and key technicians gave the visiting team a warm welcome. The two sides had a meeting, after which the expert team visited our laboratory and pilot workshop.
more >
Recently, Chengdu Maxvax Biotechnology ("Maxvax Biotech") announced that it has raised nearly RMB 500 million (approx. $74 million) from a Series B funding led by China Life Equity Investment and participated by the original shareholders Sherpa Healthcare Partners and GL Ventures, with follow-up investments from two new investors, Shizhen Capital and Xinshang Capital. The fund will mainly be used for the clinical trials of the company’s multiple vaccine pipelines, the construction of its Shanghai production base, and the expansion and improvement of its talent team.
more >
Maxvax Biotech held a grand commencement ceremony for the "Innovative Vaccine Production Platform Project" of Shanghai Maxvax Biotech, a wholly-owned subsidiary of Chengdu Maxvax Biotech, in the Lingang New Area of Shanghai on June 27, 2022. Leaders of Shanghai Lingang Fengxian Economic Development Company (Chairman Mr. Linkun Zou, Assistant General Manager Ms. Aiying Ding, and Deputy Director of Project Promotion Department Mr. Jie Duan) and leaders of Maxvax (Deputy General Manager Mr. Yi Jin and Mr. Yichun Dong), and other leaders and partners attended the event.
more >